FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer

The FDA granted accelerated approval to GSK’s neladalkib (Nelkarmi) for adults with previously treated ALK-positive metastatic or locally advanced NSCLC. Based on the Phase I/II ALKOVE-1 trial, confirmed ORR was 49% (after alectinib) and 32% (after multiple ALK TKIs plus platinum), with intracranial ORR 55% and 26%. Key safety issues included hepatotoxicity (56%).

Original reporting
Published Nov 18, 2026, 9:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The FDA’s accelerated approval adds a new targeted option for previously treated ALK-positive NSCLC, including reported intracranial activity, but the evidence base is response and duration rather than overall survival.

02

Market read

Traders may reassess GSK’s oncology pipeline value and near-term sentiment for ALK NSCLC competitors, while weighing accelerated-approval uncertainty.

03

What to watch

Eligibility is restricted to specific prior ALK TKI histories, and the safety profile highlights hepatotoxicity monitoring needs, which could constrain uptake versus broader later-line options.

Relevance 7/10Novelty 8/10Timing: FDA approval announced Nov 17, 2026, ahead of the original Nov 27 target action date.

Background

Neladalkib (Nelkarmi) received Breakthrough Therapy and Orphan Drug designations and is positioned for ALK-positive NSCLC after progression on prior ALK-directed therapies.

Company-level read

Ticker impact

$GSKBullishMedium confidence
Context

FDA granted accelerated approval to neladalkib, announced by GSK, expanding its ALK-positive NSCLC targeted therapy portfolio.

Expected impact

Likely modest positive bias as investors price in additional late-stage pipeline value, tempered by uncertainty around durability, confirmatory trial outcomes, and competitive positioning.

Evidence & confidence

The article is a direct FDA approval event tied to GSK’s announced acquisition-linked development, but it provides no revenue guidance or confirmatory readout timing, limiting near-term earnings impact visibility.

Market effects

Reinforces continued investor interest in ALK-targeted lung cancer drugs and CNS-penetrant next-generation inhibitors, potentially supporting sentiment for competing ALK franchise assets.

Primarily US regulatory-driven sentiment for global pharma with oncology exposure; limited direct regional spillover beyond biotech/healthcare.

US FDA decision can affect global treatment sequencing discussions and trial enrollment expectations for ALK-positive NSCLC programs worldwide.

Counterpoint

Because the approval is accelerated and based on response rate in a single-arm trial, the market may discount the near-term value until confirmatory survival benefit is demonstrated in ALKAZAR.

Key entities

  • Neladalkib

    Oral ALK-targeted therapy granted FDA accelerated approval for previously treated ALK-positive NSCLC.

  • ALKOVE-1

    Phase I/II single-arm trial supporting the approval, reporting confirmed ORR and duration of response.

  • ALKAZAR

    Ongoing Phase III trial comparing neladalkib with alectinib as first-line therapy.

  • GSK

    Announced the FDA approval following its acquisition of Nuvalent, linking it to neladalkib’s development.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.